
Why I’ve Just Sold My Firefinch (ASX: FFX) Shares
The stock is up but the prices of the commodities it mines are down.
The stock is up but the prices of the commodities it mines are down.
Cogstate (ASX: CGS), Pureprofile (ASX: PPL) and Genetic Signatures (ASX: GSS) each recently updated the market on Q3 FY 2022 results.
Rising interest rates result from inflation, and impact my share portfolio, my investment property, and the whole Australian economy.
These 5 stocks all give exposure to the cybersecurity mega-trend, but some are far more attractive than others…
Codan’s Minelab detection business has gone into reverse, but the share price may now compensate for that headwind.
These four companies are businesses I want to own for the long term (and I’d like to own more of, at the right price).
The thesis is certainly off track but it’s much better to think things through slowly, than panic.
This company has a few different features that mean it should fare much better than most in an inflationary environment.
These 5 well established businesses have all seen insiders snapping up shares at close to or above current prices.
EarlyPay (ASX: EPY) is growing profits strongly and recently upgraded guidance, but the business still faces notable risks.
IntelliHR (ASX: IHR) is delivering reasonably strong sales growth but the increasing executive remuneration is well worth noting.
Strong growth in H1 FY 2022 supports the view that Objective Corporation is one of the highest quality ASX business, but can it justify the share price?
The drop in recurring revenue means that the company is lower quality than I had previously believed.
Dicker Data (ASX: DDR) achieved another year of very strong profit growth, assisted by the acquisition of Exeed.
Recent study shows effectiveness drops against infection and hospitalisation for kids.
Energy One (ASX: EOL) reported a weak profit result but still grew recurring revenue by 16%, in what was a tough half.
Diverger had a flat half but that’s not bad given its attractive price. And the company has credible growth plans going forward, offering potential upside.
Symbio is setting itself up for acquisitive growth in Asia, but the stock is arguably priced for perfection.
MSL Solutions (ASX: MSL) doesn’t seem to be focussed on growing free cash flow, now that the business has been stablised.
Salvatore Zofrea is a celebrated painter and printmaker and this show celebrating his drawing traces the artist’s personal journey from Italy to the Australian landscape.